Iterum Therapeutics - רווח למניה אחת ב-12 החודשים האחרונים ITRM

Iterum Therapeutics plc (ITRM) is implementing software robots and automated screening to accelerate clinical trials. The annual percentage growth of EPS TTM illustrates the financial impact of these processes, with the latest figure standing at 62.30. The company is creating unique Orlynvq antibiotics to combat resistant urinary tract infections, developing breakthrough treatments for diseases that are unresponsive to traditional therapy.
Iterum Therapeutics PLC - פילוחים אנליטיים ומדדי מפתח (ITRM)

This metric measures the dynamics of net income per share over a rolling twelve-month period, reflecting the actual efficiency of capital generation for Iterum Therapeutics plc (ITRM). By analyzing the EPS YoY TTM growth trajectory, an investor assesses business scalability, where the high precision of robotic antibiotic filling lines should translate into cost reductions and a sustainable increase in profit.